Last 12 months
Inside the activity.
0 purchase rows · 13 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 6 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 4 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 25, 2023 Filed Apr 27, 2023 21:04 UTC |
ROMRELL LARRY EDirector
|
GrantShare Option C (right to buy) · Derivative | 14,300 | Not disclosed Strike: $27.85 | Not disclosed |
DisclosureSEC source: 0001570585-23-000147 · wf-form4_168262944655937.xml · derivative · entry 10 ROMRELL LARRY E · CIK 0001120556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,300 Underlying: Class C Ordinary Shares · 14,300 shares Expires 2027-06-21 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:04 UTC |
ROMRELL LARRY EDirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 14,300 | Not disclosed Strike: $27.85 | Not disclosed |
DisclosureSEC source: 0001570585-23-000147 · wf-form4_168262944655937.xml · derivative · entry 9 ROMRELL LARRY E · CIK 0001120556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 14,300 shares Expires 2024-06-21 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:04 UTC |
ROMRELL LARRY EDirector
|
GrantShare Option C (right to buy) · Derivative | 11,680 | Not disclosed Strike: $29.64 | Not disclosed |
DisclosureSEC source: 0001570585-23-000147 · wf-form4_168262944655937.xml · derivative · entry 8 ROMRELL LARRY E · CIK 0001120556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,680 Underlying: Class C Ordinary Shares · 11,680 shares Expires 2026-06-16 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:04 UTC |
ROMRELL LARRY EDirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 11,680 | Not disclosed Strike: $29.64 | Not disclosed |
DisclosureSEC source: 0001570585-23-000147 · wf-form4_168262944655937.xml · derivative · entry 7 ROMRELL LARRY E · CIK 0001120556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 11,680 shares Expires 2023-06-16 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:04 UTC |
ROMRELL LARRY EDirector
|
GrantShare Option A (right to buy) · Derivative | 7,941 | Not disclosed Strike: $30.14 | Not disclosed |
DisclosureSEC source: 0001570585-23-000147 · wf-form4_168262944655937.xml · derivative · entry 6 ROMRELL LARRY E · CIK 0001120556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,941 Underlying: Class A Ordinary Shares · 7,941 shares Expires 2028-06-12 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:04 UTC |
ROMRELL LARRY EDirector
|
Disposition to issuerShare Option A (right to buy) · Derivative | 7,941 | Not disclosed Strike: $30.14 | Not disclosed |
DisclosureSEC source: 0001570585-23-000147 · wf-form4_168262944655937.xml · derivative · entry 5 ROMRELL LARRY E · CIK 0001120556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 7,941 shares Expires 2025-06-12 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:04 UTC |
ROMRELL LARRY EDirector
|
GrantShare Option A (right to buy) · Derivative | 7,150 | Not disclosed Strike: $28.83 | Not disclosed |
DisclosureSEC source: 0001570585-23-000147 · wf-form4_168262944655937.xml · derivative · entry 4 ROMRELL LARRY E · CIK 0001120556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,150 Underlying: Class A Ordinary Shares · 7,150 shares Expires 2027-06-21 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:04 UTC |
ROMRELL LARRY EDirector
|
Disposition to issuerShare Option A (right to buy) · Derivative | 7,150 | Not disclosed Strike: $28.83 | Not disclosed |
DisclosureSEC source: 0001570585-23-000147 · wf-form4_168262944655937.xml · derivative · entry 3 ROMRELL LARRY E · CIK 0001120556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 7,150 shares Expires 2024-06-21 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:04 UTC |
ROMRELL LARRY EDirector
|
GrantClass A Ordinary Shares · Derivative | 5,840 | Not disclosed Strike: $30.47 | Not disclosed |
DisclosureSEC source: 0001570585-23-000147 · wf-form4_168262944655937.xml · derivative · entry 2 ROMRELL LARRY E · CIK 0001120556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,840 Underlying: Class A Ordinary Shares · 5,840 shares Expires 2026-06-16 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:04 UTC |
ROMRELL LARRY EDirector
|
Disposition to issuerShare Option A (right to buy) · Derivative | 5,840 | Not disclosed Strike: $30.47 | Not disclosed |
DisclosureSEC source: 0001570585-23-000147 · wf-form4_168262944655937.xml · derivative · entry 1 ROMRELL LARRY E · CIK 0001120556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 5,840 shares Expires 2023-06-16 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:01 UTC |
CURTIS MIRANDADirector
|
GrantShare Option C (right to buy) · Derivative | 15,882 | Not disclosed Strike: $29.07 | Not disclosed |
DisclosureSEC source: 0001570585-23-000139 · wf-form4_168262926076092.xml · derivative · entry 12 CURTIS MIRANDA · CIK 0001144689 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,882 Underlying: Class C Ordinary Shares · 15,882 shares Expires 2028-06-12 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:01 UTC |
CURTIS MIRANDADirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 15,882 | Not disclosed Strike: $29.07 | Not disclosed |
DisclosureSEC source: 0001570585-23-000139 · wf-form4_168262926076092.xml · derivative · entry 11 CURTIS MIRANDA · CIK 0001144689 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 15,882 shares Expires 2025-06-12 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:01 UTC |
CURTIS MIRANDADirector
|
GrantShare Option C (right to buy) · Derivative | 14,300 | Not disclosed Strike: $27.85 | Not disclosed |
DisclosureSEC source: 0001570585-23-000139 · wf-form4_168262926076092.xml · derivative · entry 10 CURTIS MIRANDA · CIK 0001144689 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,300 Underlying: Class C Ordinary Shares · 14,300 shares Expires 2027-06-21 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:01 UTC |
CURTIS MIRANDADirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 14,300 | Not disclosed Strike: $27.85 | Not disclosed |
DisclosureSEC source: 0001570585-23-000139 · wf-form4_168262926076092.xml · derivative · entry 9 CURTIS MIRANDA · CIK 0001144689 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 14,300 shares Expires 2024-06-21 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:01 UTC |
CURTIS MIRANDADirector
|
GrantShare Option C (right to buy) · Derivative | 11,680 | Not disclosed Strike: $29.64 | Not disclosed |
DisclosureSEC source: 0001570585-23-000139 · wf-form4_168262926076092.xml · derivative · entry 8 CURTIS MIRANDA · CIK 0001144689 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,680 Underlying: Class C Ordinary Shares · 11,680 shares Expires 2026-06-16 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:01 UTC |
CURTIS MIRANDADirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 11,680 | Not disclosed Strike: $29.64 | Not disclosed |
DisclosureSEC source: 0001570585-23-000139 · wf-form4_168262926076092.xml · derivative · entry 7 CURTIS MIRANDA · CIK 0001144689 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 11,680 shares Expires 2023-06-16 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:01 UTC |
CURTIS MIRANDADirector
|
GrantShare Option A (right to buy) · Derivative | 7,941 | Not disclosed Strike: $30.14 | Not disclosed |
DisclosureSEC source: 0001570585-23-000139 · wf-form4_168262926076092.xml · derivative · entry 6 CURTIS MIRANDA · CIK 0001144689 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,941 Underlying: Class A Ordinary Shares · 7,941 shares Expires 2028-06-12 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:01 UTC |
CURTIS MIRANDADirector
|
Disposition to issuerShare Option A (right to buy) · Derivative | 7,941 | Not disclosed Strike: $30.14 | Not disclosed |
DisclosureSEC source: 0001570585-23-000139 · wf-form4_168262926076092.xml · derivative · entry 5 CURTIS MIRANDA · CIK 0001144689 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 7,941 shares Expires 2025-06-12 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:01 UTC |
CURTIS MIRANDADirector
|
GrantShare Option A (right to buy) · Derivative | 7,150 | Not disclosed Strike: $28.83 | Not disclosed |
DisclosureSEC source: 0001570585-23-000139 · wf-form4_168262926076092.xml · derivative · entry 4 CURTIS MIRANDA · CIK 0001144689 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,150 Underlying: Class A Ordinary Shares · 7,150 shares Expires 2027-06-21 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:01 UTC |
CURTIS MIRANDADirector
|
Disposition to issuerShare Option A (right to buy) · Derivative | 7,150 | Not disclosed Strike: $28.83 | Not disclosed |
DisclosureSEC source: 0001570585-23-000139 · wf-form4_168262926076092.xml · derivative · entry 3 CURTIS MIRANDA · CIK 0001144689 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 7,150 shares Expires 2024-06-21 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:01 UTC |
CURTIS MIRANDADirector
|
GrantShare Option A (right to buy) · Derivative | 5,840 | Not disclosed Strike: $30.47 | Not disclosed |
DisclosureSEC source: 0001570585-23-000139 · wf-form4_168262926076092.xml · derivative · entry 2 CURTIS MIRANDA · CIK 0001144689 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,840 Underlying: Class A Ordinary Shares · 5,840 shares Expires 2026-06-16 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:01 UTC |
CURTIS MIRANDADirector
|
Disposition to issuerShare Option A (right to buy) · Derivative | 5,840 | Not disclosed Strike: $30.47 | Not disclosed |
DisclosureSEC source: 0001570585-23-000139 · wf-form4_168262926076092.xml · derivative · entry 1 CURTIS MIRANDA · CIK 0001144689 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 5,840 shares Expires 2023-06-16 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 17:01 UTC |
DICK JOHN WDirector
|
GrantShare Option C (right to buy) · Derivative | 15,882 | Not disclosed Strike: $29.07 | Not disclosed |
DisclosureSEC source: 0001570585-23-000140 · wf-form4_168262928583872.xml · derivative · entry 12 DICK JOHN W · CIK 0001145585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,882 Underlying: Class C Ordinary Shares · 15,882 shares Expires 2028-06-12 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 17:01 UTC |
DICK JOHN WDirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 15,882 | Not disclosed Strike: $29.07 | Not disclosed |
DisclosureSEC source: 0001570585-23-000140 · wf-form4_168262928583872.xml · derivative · entry 11 DICK JOHN W · CIK 0001145585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 15,882 shares Expires 2025-06-12 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 17:01 UTC |
DICK JOHN WDirector
|
GrantShare Option C (right to buy) · Derivative | 14,300 | Not disclosed Strike: $27.85 | Not disclosed |
DisclosureSEC source: 0001570585-23-000140 · wf-form4_168262928583872.xml · derivative · entry 10 DICK JOHN W · CIK 0001145585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,300 Underlying: Class C Ordinary Shares · 14,300 shares Expires 2027-06-21 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 17:01 UTC |
DICK JOHN WDirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 14,300 | Not disclosed Strike: $27.85 | Not disclosed |
DisclosureSEC source: 0001570585-23-000140 · wf-form4_168262928583872.xml · derivative · entry 9 DICK JOHN W · CIK 0001145585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 14,300 shares Expires 2024-06-21 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 17:01 UTC |
DICK JOHN WDirector
|
GrantShare Option C (right to buy) · Derivative | 11,680 | Not disclosed Strike: $29.64 | Not disclosed |
DisclosureSEC source: 0001570585-23-000140 · wf-form4_168262928583872.xml · derivative · entry 8 DICK JOHN W · CIK 0001145585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,680 Underlying: Class C Ordinary Shares · 11,680 shares Expires 2026-06-16 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 17:01 UTC |
DICK JOHN WDirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 11,680 | Not disclosed Strike: $29.64 | Not disclosed |
DisclosureSEC source: 0001570585-23-000140 · wf-form4_168262928583872.xml · derivative · entry 7 DICK JOHN W · CIK 0001145585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 11,680 shares Expires 2023-06-16 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 17:01 UTC |
DICK JOHN WDirector
|
GrantShare Option A (right to buy) · Derivative | 7,941 | Not disclosed Strike: $30.14 | Not disclosed |
DisclosureSEC source: 0001570585-23-000140 · wf-form4_168262928583872.xml · derivative · entry 6 DICK JOHN W · CIK 0001145585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,941 Underlying: Class A Ordinary Shares · 7,941 shares Expires 2028-06-12 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 17:01 UTC |
DICK JOHN WDirector
|
Disposition to issuerShare Option A (right to buy) · Derivative | 7,941 | Not disclosed Strike: $30.14 | Not disclosed |
DisclosureSEC source: 0001570585-23-000140 · wf-form4_168262928583872.xml · derivative · entry 5 DICK JOHN W · CIK 0001145585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 7,941 shares Expires 2025-06-12 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 17:01 UTC |
DICK JOHN WDirector
|
GrantShare Option A (right to buy) · Derivative | 7,150 | Not disclosed Strike: $28.83 | Not disclosed |
DisclosureSEC source: 0001570585-23-000140 · wf-form4_168262928583872.xml · derivative · entry 4 DICK JOHN W · CIK 0001145585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,150 Underlying: Class A Ordinary Shares · 7,150 shares Expires 2027-06-21 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 17:01 UTC |
DICK JOHN WDirector
|
Disposition to issuerShare Option A (right to buy) · Derivative | 7,150 | Not disclosed Strike: $28.83 | Not disclosed |
DisclosureSEC source: 0001570585-23-000140 · wf-form4_168262928583872.xml · derivative · entry 3 DICK JOHN W · CIK 0001145585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 7,150 shares Expires 2024-06-21 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 17:01 UTC |
DICK JOHN WDirector
|
GrantShare Option A (right to buy) · Derivative | 5,840 | Not disclosed Strike: $30.47 | Not disclosed |
DisclosureSEC source: 0001570585-23-000140 · wf-form4_168262928583872.xml · derivative · entry 2 DICK JOHN W · CIK 0001145585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,840 Underlying: Class A Ordinary Shares · 5,840 shares Expires 2026-06-16 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 17:01 UTC |
DICK JOHN WDirector
|
Disposition to issuerShare Option A (right to buy) · Derivative | 5,840 | Not disclosed Strike: $30.47 | Not disclosed |
DisclosureSEC source: 0001570585-23-000140 · wf-form4_168262928583872.xml · derivative · entry 1 DICK JOHN W · CIK 0001145585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 5,840 shares Expires 2023-06-16 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:05 UTC |
Waldron JasonSVP & CAO
|
GrantShare Appreciation Rights C · Derivative | 52,286 | Not disclosed Strike: $28.94 | Not disclosed |
DisclosureSEC source: 0001570585-23-000149 · wf-form4_168262950837650.xml · derivative · entry 12 Waldron Jason · CIK 0001693396 · SVP & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,286 Underlying: Class C Ordinary Shares · 52,286 shares Expires 2028-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:05 UTC |
Waldron JasonSVP & CAO
|
Disposition to issuerShare Appreciation Rights C · Derivative | 52,286 | Not disclosed Strike: $28.94 | Not disclosed |
DisclosureSEC source: 0001570585-23-000149 · wf-form4_168262950837650.xml · derivative · entry 11 Waldron Jason · CIK 0001693396 · SVP & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 52,286 shares Expires 2025-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:05 UTC |
Waldron JasonSVP & CAO
|
GrantShare Appreciation Rights C · Derivative | 45,568 | Not disclosed Strike: $34.80 | Not disclosed |
DisclosureSEC source: 0001570585-23-000149 · wf-form4_168262950837650.xml · derivative · entry 10 Waldron Jason · CIK 0001693396 · SVP & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,568 Underlying: Class C Ordinary Shares · 45,568 shares Expires 2027-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:05 UTC |
Waldron JasonSVP & CAO
|
Disposition to issuerShare Appreciation Rights C · Derivative | 45,568 | Not disclosed Strike: $34.80 | Not disclosed |
DisclosureSEC source: 0001570585-23-000149 · wf-form4_168262950837650.xml · derivative · entry 9 Waldron Jason · CIK 0001693396 · SVP & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 45,568 shares Expires 2024-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:05 UTC |
Waldron JasonSVP & CAO
|
GrantShare Appreciation Rights C · Derivative | 48,708 | Not disclosed Strike: $31.61 | Not disclosed |
DisclosureSEC source: 0001570585-23-000149 · wf-form4_168262950837650.xml · derivative · entry 8 Waldron Jason · CIK 0001693396 · SVP & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,708 Underlying: Class C Ordinary Shares · 48,708 shares Expires 2026-11-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:05 UTC |
Waldron JasonSVP & CAO
|
Disposition to issuerShare Appreciation Rights C · Derivative | 48,708 | Not disclosed Strike: $31.61 | Not disclosed |
DisclosureSEC source: 0001570585-23-000149 · wf-form4_168262950837650.xml · derivative · entry 7 Waldron Jason · CIK 0001693396 · SVP & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 48,708 shares Expires 2023-11-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:05 UTC |
Waldron JasonSVP & CAO
|
GrantShare Appreciation Rights A · Derivative | 26,143 | Not disclosed Strike: $29.88 | Not disclosed |
DisclosureSEC source: 0001570585-23-000149 · wf-form4_168262950837650.xml · derivative · entry 6 Waldron Jason · CIK 0001693396 · SVP & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,143 Underlying: Class A Ordinary Shares · 26,143 shares Expires 2028-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:05 UTC |
Waldron JasonSVP & CAO
|
Disposition to issuerShare Appreciation Rights A · Derivative | 26,143 | Not disclosed Strike: $29.88 | Not disclosed |
DisclosureSEC source: 0001570585-23-000149 · wf-form4_168262950837650.xml · derivative · entry 5 Waldron Jason · CIK 0001693396 · SVP & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 26,143 shares Expires 2025-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:05 UTC |
Waldron JasonSVP & CAO
|
GrantShare Appreciation Rights A · Derivative | 22,784 | Not disclosed Strike: $35.69 | Not disclosed |
DisclosureSEC source: 0001570585-23-000149 · wf-form4_168262950837650.xml · derivative · entry 4 Waldron Jason · CIK 0001693396 · SVP & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,784 Underlying: Class A Ordinary Shares · 22,784 shares Expires 2027-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:05 UTC |
Waldron JasonSVP & CAO
|
Disposition to issuerShare Appreciation Rights A · Derivative | 22,784 | Not disclosed Strike: $35.69 | Not disclosed |
DisclosureSEC source: 0001570585-23-000149 · wf-form4_168262950837650.xml · derivative · entry 3 Waldron Jason · CIK 0001693396 · SVP & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 22,784 shares Expires 2024-05-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:05 UTC |
Waldron JasonSVP & CAO
|
GrantShare Appreciation Rights A · Derivative | 24,354 | Not disclosed Strike: $32.26 | Not disclosed |
DisclosureSEC source: 0001570585-23-000149 · wf-form4_168262950837650.xml · derivative · entry 2 Waldron Jason · CIK 0001693396 · SVP & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,354 Underlying: Class A Ordinary Shares · 24,354 shares Expires 2026-11-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:05 UTC |
Waldron JasonSVP & CAO
|
Disposition to issuerShare Appreciation Rights A · Derivative | 24,354 | Not disclosed Strike: $32.26 | Not disclosed |
DisclosureSEC source: 0001570585-23-000149 · wf-form4_168262950837650.xml · derivative · entry 1 Waldron Jason · CIK 0001693396 · SVP & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 24,354 shares Expires 2023-11-01 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share appreciation rights (SAR) for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding SAR were to be cancelled and replaced by a new SAR. However, from the Issuer's perspective, no new SAR is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing SAR has not changed as a result of the extension and therefore the SAR continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:03 UTC |
Green Richard RDirector
|
GrantShare Option C (right to buy) · Derivative | 15,882 | Not disclosed Strike: $29.07 | Not disclosed |
DisclosureSEC source: 0001570585-23-000143 · wf-form4_168262936685142.xml · derivative · entry 12 Green Richard R · CIK 0001452212 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,882 Underlying: Class C Ordinary Shares · 15,882 shares Expires 2028-06-12 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:03 UTC |
Green Richard RDirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 15,882 | Not disclosed Strike: $29.07 | Not disclosed |
DisclosureSEC source: 0001570585-23-000143 · wf-form4_168262936685142.xml · derivative · entry 11 Green Richard R · CIK 0001452212 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 15,882 shares Expires 2025-06-12 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:03 UTC |
Green Richard RDirector
|
GrantShare Option C (right to buy) · Derivative | 14,300 | Not disclosed Strike: $27.85 | Not disclosed |
DisclosureSEC source: 0001570585-23-000143 · wf-form4_168262936685142.xml · derivative · entry 10 Green Richard R · CIK 0001452212 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,300 Underlying: Class C Ordinary Shares · 14,300 shares Expires 2027-06-21 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:03 UTC |
Green Richard RDirector
|
Disposition to issuerShare Option C (right to buy) · Derivative | 14,300 | Not disclosed Strike: $27.85 | Not disclosed |
DisclosureSEC source: 0001570585-23-000143 · wf-form4_168262936685142.xml · derivative · entry 9 Green Richard R · CIK 0001452212 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class C Ordinary Shares · 14,300 shares Expires 2024-06-21 F1 · kind: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · price: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F1 · derivative.exercise_date: The reported transactions involve an extension of the seven-year exercise period on existing share options for an additional three-year period. For Form 4 reporting purposes, this is shown as if the outstanding option were to be cancelled and replaced by a new option. However, from the Issuer's perspective, no new option is issued, the Issuer has only extended the expiration term on the original grant, with the same pricing and other terms continuing to apply. F2 · derivative.exercise_date: Vesting and exercise of the existing option has not changed as a result of the extension and therefore the option continues to be immediately exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.